Recent Updates
Recently added Catalysts
JNJ Positive Sentiment

Samenvatting: Johnson & Johnson ontvangt CE-markering voor herbruikbare ACUVUE OASYS MAX-contactlenzen

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Johnson & Johnson has announced the receipt of CE marking for its new ACUVUE OASYS MAX 2-Week contact lenses. These reusable lenses incorporate MAX technologies aimed at providing enhanced comfort and visual clarity throughout their 14-day usage period. This approval marks a significant advancement in their product offerings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Johnson & Johnson has received CE marking for a new product.
  • The ACUVUE OASYS MAX lenses are designed for superior comfort.
  • The lenses maintain visual clarity even after 14 days of use.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Canagliflozin
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

LIMERICK, Ierland--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) heeft vandaag aangekondigd dat het de CE-markering heeft ontvangen voor ACUVUE OASYS MAX 2-Week,*** een nieuwe herbruikbare contactlens met eigen MAX-technologieën, ontworpen voor superieur comfort en visuele helderheid, zelfs op dag 14. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgel

Frequently Asked Questions

What is the ACUVUE OASYS MAX?

The ACUVUE OASYS MAX is a new reusable contact lens designed for comfort and clarity.

What does CE marking signify?

CE marking indicates that a product meets EU safety and health requirements.

How long can ACUVUE OASYS MAX lenses be used?

These lenses can be used for up to 14 days.

Who manufactures ACUVUE OASYS MAX lenses?

ACUVUE OASYS MAX lenses are manufactured by Johnson & Johnson.

ShareAdd on Google
Tags: JNJ Viatris Investor Conferences Healthcare Johnson & Johnson CE marking contact lenses ACUVUE OASYS MAX optical technology
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$20758M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CanagliflozinPhase 3
Diabetes Mellitus, Type 2 →

Catalyst track record

+34%
best trade around JNJ's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for JNJ.

See every catalyst's timing & PoA →